Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2019


Biomarker-based Strategy to Solve Resistance to Immunotherapy

RJ Tesi, CEO/CMO, Inmune Bio Inc

In cancer, resistance to immunotherapy can be managed differently than resistance to chemotherapy.  Resistance to immunotherapy does not mean abandoning the immunotherapy, but adding a second immunotherapy that overcomes the immunologic resistance mechanism.  Combination immunotherapy should be precision medicine based of rational, biologically based and measurable biomarkers to select the subset of patients who will be sensitive to therapy.  Preclinical data on resistance immune checkpoint inhibitors and trastuzumab resistance will be used as case studies.

Add to Calendar ▼2019-10-30 00:00:002019-11-01 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The